Gabify: Bringing AI to Early Neurodevelopmental Care
October 27, 2026 | Tuesday | Features
Gabify is building an AI-powered ecosystem to make early screening and therapy support more accessible for children with neurodevelopmental and speech-related needs. Founded in 2023, the Noida-based health-tech startup combines voice and visual AI with clinical oversight to help identify developmental concerns earlier and connect families with therapists, clinics and other care providers.
Problem
Children with autism, ADHD and speech delays may face long waits for assessment, limited access to specialists and fragmented therapy support. Gabify aims to address these gaps through faster screening, digital care coordination and more accessible pathways to professional support.
Product
Gabify's Neurolens uses voice and visual AI to analyse speech patterns, facial expressions, eye gaze and behavioural markers across more than 189 criteria. Its wider platform combines clinical practice management, therapist connectivity and parent-facing care tools, with human clinical review supporting AI-generated outputs.
Proof
Gabify has reported pilot deployments across more than 35 preschools and daycare centres, with adoption extending to schools, hospitals and clinics. Its website lists more than 2,500 AI-assisted screenings, 50-plus clinics and institutions, and 300-plus clinicians across 12-plus operational locations.
People
Gabify was co-founded by Sahil Chopra, Prachi Sood and Vasyl Leshchuk. The team combines startup leadership, speech therapy expertise and technology development to build solutions for children's neurodevelopmental screening and care.
Purse
In April 2026, Gabify raised $175,000 in pre-seed funding, led by Inflection Point Ventures (IPV). It also received a ₹25 lakh grant under the NIDHI Seed Support Scheme through GHRTBI to support clinical validation, technology development and team expansion.
Plan
Gabify plans to expand through business-to-business, direct-to-consumer and CSR-led initiatives, reaching more families through schools, clinics and healthcare institutions. Its stated ambition is to positively impact one million children by 2028 while strengthening clinical validation and its AI-powered care ecosystem.
Why it matters:
By combining AI-assisted screening with professional oversight and digital therapy coordination, Gabify is addressing gaps in early neurodevelopmental care. Its approach could help families access timely assessments and appropriate support, particularly in underserved communities.
FAST FACTS
|
Category
|
Details
|
|
Company
|
Gabify (Sahchi Hearing and Speech Solutions Pvt. Ltd.)
|
|
Founded
|
2023
|
|
Headquarters
|
Noida, Uttar Pradesh
|
|
Industry
|
HealthTech, AI diagnostics, neurodevelopmental care
|
|
Founders
|
Sahil Chopra, Prachi Sood and Vasyl Leshchuk
|
|
Core offering
|
AI-assisted screening and digital therapy management
|
|
Flagship product
|
Neurolens
|
|
Technology
|
Voice and visual AI with human clinical review
|
|
Latest funding
|
$175,000 pre-seed, April 2026
|
|
Lead investor
|
Inflection Point Ventures
|
|
Additional support
|
₹25 lakh NIDHI Seed Support Scheme grant
|
|
Next
|
Strengthen clinical validation and expand access, targeting one million children by 2028
|
Disclaimer: This profile is independent editorial content based on publicly available information and company disclosures reviewed in October 2026. Screening technology is not a substitute for a comprehensive assessment by qualified healthcare professionals. Company-reported metrics should be verified before publication.
